Oxygenta Pharmaceutical (BOM:524636) Cyclically Adjusted Revenue per Share: ₹31.45 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524636 Oxygenta Pharmaceutical Ltd BOM:524636
44 GF Score
Price ₹59.48
GF Value ₹84.93
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Oxygenta Pharmaceutical Cyclically Adjusted Revenue per Share?

Oxygenta Pharmaceutical BOM:524636 +4.52% 44 Cyclically Adjusted Revenue per Share is ₹31.45 as of Jun. 2026. GuruFocus rates BOM:524636 with a GF Score™ of 44/100 and a GF Value™ of ₹84.93 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Oxygenta Pharmaceutical's adjusted revenue per share for the three months ended in Jun. 2026 was ₹10.024. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹31.45 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Oxygenta Pharmaceutical's average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-27), Oxygenta Pharmaceutical's current stock price is ₹59.48. Oxygenta Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹31.45. Oxygenta Pharmaceutical's Cyclically Adjusted PS Ratio of today is 1.89.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Oxygenta Pharmaceutical was 4.54. The lowest was 1.02. And the median was 1.84.


Oxygenta Pharmaceutical  (BOM:524636) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Oxygenta Pharmaceutical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=59.48/31.45
=1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Oxygenta Pharmaceutical was 4.54. The lowest was 1.02. And the median was 1.84.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Oxygenta Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms


Oxygenta Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Oxygenta Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxygenta Pharmaceutical Cyclically Adjusted Revenue per Share Chart

Oxygenta Pharmaceutical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 24.57 27.39 30.20

Oxygenta Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.17 28.90 29.19 30.20 31.45

BOM:524636 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Oxygenta Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxygenta Pharmaceutical Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Oxygenta Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Oxygenta Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


BOM:524636
44GF Score
Oxygenta Pharmaceutical Ltd BOM:524636
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxygenta Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oxygenta Pharmaceutical's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=10.024/167.3573*167.3573
=10.024

Current CPI (Jun. 2026) = 167.3573.

Oxygenta Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.110 105.961 1.753
201612 3.076 105.196 4.894
201703 1.765 105.196 2.808
201706 2.052 107.109 3.206
201709 2.256 109.021 3.463
201712 2.878 109.404 4.403
201803 5.420 109.786 8.262
201806 8.970 111.317 13.486
201809 5.899 115.142 8.574
201812 2.977 115.142 4.327
201903 3.690 118.202 5.225
201906 3.484 120.880 4.824
201909 3.964 123.175 5.386
201912 3.842 126.235 5.094
202003 2.146 124.705 2.880
202006 3.255 127.000 4.289
202009 8.217 130.118 10.569
202012 28.547 130.889 36.501
202103 10.871 131.771 13.807
202106 21.391 134.084 26.699
202109 11.002 135.847 13.554
202112 10.962 138.161 13.279
202203 4.982 138.822 6.006
202206 6.247 142.347 7.345
202209 4.252 144.661 4.919
202212 5.532 145.763 6.352
202303 5.753 146.865 6.556
202306 2.484 150.280 2.766
202309 3.600 151.492 3.977
202312 2.714 152.924 2.970
202403 2.677 153.035 2.928
202406 3.610 155.789 3.878
202409 3.975 157.882 4.214
202412 9.045 158.323 9.561
202503 13.797 157.552 14.656
202506 4.090 159.755 4.285
202509 3.858 162.289 3.978
202512 9.248 163.281 9.479
202603 13.103 164.272 13.349
202606 10.024 167.357 10.024

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹31.45 mean?
Oxygenta Pharmaceutical (BOM:524636) has a Cyclically Adjusted Revenue per Share of ₹31.45 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Oxygenta Pharmaceutical and its competitors.
Is Oxygenta Pharmaceutical's Cyclically Adjusted Revenue per Share too high?
Oxygenta Pharmaceutical's current Cyclically Adjusted Revenue per Share is ₹31.45. Overall, Oxygenta Pharmaceutical has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Oxygenta Pharmaceutical's Cyclically Adjusted Revenue per Share compare to ZTS?
Oxygenta Pharmaceutical's Cyclically Adjusted Revenue per Share of ₹31.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Oxygenta Pharmaceutical and its competitors. Oxygenta Pharmaceutical's current Cyclically Adjusted Revenue per Share is ₹31.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxygenta Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Oxygenta Pharmaceutical (BOM:524636) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹84.93, compared to a current price of ₹59.48 — trading 30% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹31.45. Oxygenta Pharmaceutical's overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Oxygenta Pharmaceutical (BOM:524636), the current Cyclically Adjusted Revenue per Share is ₹31.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxygenta Pharmaceutical (BOM:524636) Overvalued in 2026?

Based on GuruFocus' analysis, Oxygenta Pharmaceutical stock appears to be undervalued. The current stock price of ₹59.48 is trading 30% below its estimated GF Value™ of ₹84.93. GuruFocus considers Oxygenta Pharmaceutical to be Modestly Undervalued.

Key valuation signals for BOM:524636:

  • Cyclically Adjusted Revenue per Share: ₹31.45
  • GF Value™: ₹84.93 vs. price of ₹59.48 (30% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the BOM:524636 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oxygenta Pharmaceutical Business Description

Address Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad, TG, IND, 500037
Oxygenta Pharmaceutical Ltd is a pharmaceutical company. It is engaged in the business activity of is engaged in manufacturing and selling of Pharmaceutical, medical, and veterinary preparations. The Company has one reportable segment, which is Pharmaceutical. The group carries out its business operations within India.
44GF Score

Get the complete analysis for BOM:524636

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹59.48
Price
₹84.93
GF Value